SAN FRANCISCO, CA, Osanni Bio, a development-stage therapeutics platform reinventing discovery and development of new medicines, announced the close of a $190 million Series B financing.
Continue Reading
Sign up for FREE to read the full article and access 147K+ alternative investment headlines.